Anti-breast cancer sinomenine derivatives via mechanisms of apoptosis induction and metastasis reduction
- PMID: 35801430
- PMCID: PMC9272937
- DOI: 10.1080/14756366.2022.2096020
Anti-breast cancer sinomenine derivatives via mechanisms of apoptosis induction and metastasis reduction
Abstract
Sinomenine, a morphinane-type isoquinoline-derived alkaloid, was first isolated from stems and roots of Sinomenium diversifolius (Miq.) in 1920. Later discovery by researchers confirmed various essential biological efficacy sinomenine exerted in vitro and in vivo. In this study, a series of 15 sinomenine/furoxan hybrid compounds were designed and synthesised in search of a TNBC drug candidate. Some of the target compounds exhibited strong antiproliferative activities against cancer cell lines, especially for TNBC cells, compared to positive controls. Among them, hybrid 7Cc exerted superior cytotoxic effects on cancer cell lines with exceptionally low IC50 (0.82 μM) against MDA-MB-231 cells with the highest safety index score. Further studies in mechanism displayed that 7Cc could induce an S phase cell cycle arrest, stimulate apoptosis in MDA-MB-231 cells, disrupt mitochondrial membrane potential and exert a genotoxic effect on DNA in cancer cells. In addition, 7Cc also notably inhibited MDA-MB-231 cells in both migration, invasion and adhesion.
Keywords: Sinomenine; apoptosis; breast cancer; furoxan.
Conflict of interest statement
No potential conflict of interest was reported by the author(s).
Figures








Similar articles
-
Sinomenine inhibits hypoxia induced breast cancer side population cells metastasis by PI3K/Akt/mTOR pathway.Bioorg Med Chem. 2021 Feb 1;31:115986. doi: 10.1016/j.bmc.2020.115986. Epub 2020 Dec 30. Bioorg Med Chem. 2021. PMID: 33412412
-
Sinomenine inhibits breast cancer cell invasion and migration by suppressing NF-κB activation mediated by IL-4/miR-324-5p/CUEDC2 axis.Biochem Biophys Res Commun. 2015 Aug 28;464(3):705-10. doi: 10.1016/j.bbrc.2015.07.004. Epub 2015 Jul 10. Biochem Biophys Res Commun. 2015. PMID: 26166821
-
Sinomenine restrains breast cancer cells proliferation, migration and invasion via modulation of miR-29/PDCD-4 axis.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3839-3846. doi: 10.1080/21691401.2019.1666861. Artif Cells Nanomed Biotechnol. 2019. PMID: 31556312
-
Recent Advances in the Therapeutic Potential of Sinomenine for Cancer Treatment.Pharmacology. 2024;109(2):76-85. doi: 10.1159/000536133. Epub 2024 Jan 30. Pharmacology. 2024. PMID: 38290489 Review.
-
Pharmacology of sinomenine, an anti-rheumatic alkaloid from Sinomenium acutum.Acta Med Okayama. 1976 Feb;30(1):1-20. Acta Med Okayama. 1976. PMID: 61710 Review.
Cited by
-
Molecular Mechanistic Pathways Targeted by Natural Compounds in the Prevention and Treatment of Diabetic Kidney Disease.Molecules. 2022 Sep 21;27(19):6221. doi: 10.3390/molecules27196221. Molecules. 2022. PMID: 36234757 Free PMC article. Review.
-
Bioactivities and Mechanisms of Action of Sinomenine and Its Derivatives: A Comprehensive Review.Molecules. 2024 Jan 22;29(2):540. doi: 10.3390/molecules29020540. Molecules. 2024. PMID: 38276618 Free PMC article. Review.
-
Advances in mitophagy and mitochondrial apoptosis pathway-related drugs in glioblastoma treatment.Front Pharmacol. 2023 Jun 30;14:1211719. doi: 10.3389/fphar.2023.1211719. eCollection 2023. Front Pharmacol. 2023. PMID: 37456742 Free PMC article. Review.
References
-
- International Agency for Research on Cancer, Global Cancer Observatory. Available from: https://gco.iarc.fr/today/home.
-
- Torre LA, Bray F, Siegel RL, et al. . Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–105. - PubMed
-
- Rebecca LS, Kimberly DM, Fuchs HE, Ahmedin J.. Cancer statistics, 2022. CA Cancer J Clin 2022;65:87–108. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous